{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:08:41Z","timestamp":1789661321054,"version":"4.0.1"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1197335"],"award-info":[{"award-number":["1197335"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023280","name":"Seqirus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","award":["EL-2"],"award-info":[{"award-number":["EL-2"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","award":["1195894"],"award-info":[{"award-number":["1195894"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128399","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T03:42:32Z","timestamp":1772509352000},"page":"128399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Immunisation against vaccine-preventable diseases in individuals receiving immunosuppressive targeted therapies"],"prefix":"10.1016","volume":"78","author":[{"given":"Xia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyra","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketaki","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Macartney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie L.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe C.M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128399_bb0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DHPS.S28801","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","author":"Ali","year":"2013","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.vaccine.2026.128399_bb0010","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00035-19","article-title":"Infectious complications of biological and small molecule targeted immunomodulatory therapies","volume":"33","author":"Davis","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2026.128399_bb0015","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-397918-6.00001-X","article-title":"Catalytic mechanisms and regulation of protein kinases","volume":"548","author":"Wang","year":"2014","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0025","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.clinthera.2010.10.011","article-title":"Safety profile of abatacept in rheumatoid arthritis: a review","volume":"32","author":"Khraishi","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2026.128399_bb0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3899\/jrheum.091066","article-title":"Abatacept for rheumatoid arthritis: a Cochrane systematic review","volume":"37","author":"Maxwell","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/rheumatology\/ket221","article-title":"Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection","volume":"53","author":"Fanouriakis","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.vaccine.2026.128399_bb0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40360-016-0060-2","article-title":"Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report","volume":"17","author":"Talotta","year":"2016","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0045","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.clinthera.2010.10.011","article-title":"Safety profile of abatacept in rheumatoid arthritis: a review","volume":"32","author":"Khraishi","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2026.128399_bb0050","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.immuni.2007.09.002","article-title":"Antibodies and B cell memory in viral immunity","volume":"27","author":"Dorner","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128399_bb0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0060","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vaccine.2026.128399_bb0065","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2026.128399_bb0070","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/cid\/ciaa131","article-title":"Serious infectious complications after rituximab therapy in patients with autoimmunity: is this the final word?","volume":"72","author":"Gkrania-Klotsas","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1471-2334-13-317","article-title":"Infections in patients taking rituximab for hematologic malignancies: two-year cohort study","volume":"13","author":"Lanini","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40259-013-0074-x","article-title":"Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and Meta-analysis","volume":"28","author":"Borba","year":"2014","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2026.128399_bb0085","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vaccine.2026.128399_bb0090","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/apt.13215","article-title":"Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease","volume":"41","author":"Luthra","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2026.128399_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101863","article-title":"The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis","volume":"39","author":"Foley","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.vaccine.2026.128399_bb0100","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch rheumatoid arthritis monitoring (DREAM) registry","volume":"72","author":"van Dartel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/1060028018754896","article-title":"Biologic-induced infections in inflammatory bowel disease: the TNF-alpha antagonists","volume":"52","author":"McConachie","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.vaccine.2026.128399_bb0110","doi-asserted-by":"crossref","DOI":"10.4161\/mabs.3.5.16553","article-title":"Infections associated with monoclonal antibody and fusion protein therapy in humans","volume":"3","author":"Uettwiller","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.vaccine.2026.128399_bb0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.semarthrit.2015.02.006","article-title":"Anakinra for the treatment of acute severe gout in critically ill patients","volume":"45","author":"Thueringer","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128399_bb0120","article-title":"Interleukin-1 inhibitors for acute gout","author":"Sivera","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2026.128399_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/ar4159","article-title":"Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator","volume":"15","author":"Terkeltaub","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128399_bb0130","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2026.128399_bb0135","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with Canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2026.128399_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.09.052","article-title":"Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials","volume":"78","author":"Fleming","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0150","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2026.128399_bb0155","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/rheumatology\/key121","article-title":"Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.vaccine.2026.128399_bb0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1759720X17752037","article-title":"Efficacy and safety of sarilumab in patients with active rheumatoid arthritis","volume":"10","author":"McCarty","year":"2018","journal-title":"Therapeutic Advances in Musculoskeletal Disease"},{"key":"10.1016\/j.vaccine.2026.128399_bb0165","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3899\/jrheum.120687","article-title":"Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure","volume":"40","author":"Mark","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0170","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Ajinkya","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0175","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.vaccine.2026.128399_bb0180","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s41598-023-50013-7","article-title":"Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database","volume":"14","author":"Eshwar","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128399_bb0185","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0190","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128399_bb0195","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of Tofacitinib in patients with rheumatoid arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.vaccine.2026.128399_bb0200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbspin.2016.04.001","article-title":"Herpes zoster: risk and prevention during immunomodulating therapy","volume":"84","author":"Tran","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.vaccine.2026.128399_bb0205","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/cncr.11665","article-title":"Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome\u2013positive chronic myelogenous leukemia treated with interferon-\u03b1 regimens for early chronic phase","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2026.128399_bb0210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s15010-017-1105-1","article-title":"Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature","volume":"46","author":"Knoll","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2026.128399_bb0215","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/10245332.2017.1321882","article-title":"Hepatitis B reactivation in patients receiving targeted therapies","volume":"22","author":"Chang","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.vaccine.2026.128399_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by Ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.vaccine.2026.128399_bb0225","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood.V130.Suppl_1.830.830","article-title":"Incidence and type of opportunistic infections during Ibrutinib treatment at a single academic center","volume":"130","author":"Rogers","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2026.128399_bb0230","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2026.128399_bb0235","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/ker389","article-title":"Protective effect of a\/H1N1 vaccination in immune-mediated disease\u2014a prospectively controlled vaccination study","volume":"51","author":"Adler","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.vaccine.2026.128399_bb0240","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/acr.21838","article-title":"Abatacept and reduced immune response to pandemic 2009 influenza a\/H1N1 vaccination in patients with rheumatoid arthritis","volume":"65","author":"Ribeiro","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.vaccine.2026.128399_bb0245","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12891-016-1082-z","article-title":"Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept","volume":"17","author":"Alten","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.vaccine.2026.128399_bb0250","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/rheumatology\/kes202","article-title":"TNF blockers show distinct patterns of immune response to the pandemic influenza a H1N1 vaccine in inflammatory arthritis patients","volume":"51","author":"Fran\u00e7a","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vaccine.2026.128399_bb0255","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2005.036434","article-title":"Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers","volume":"65","author":"Fomin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0260","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2020.07.018","article-title":"A retrospective cohort study confirms that prophylactic vaccination is underused in patients on tumor necrosis factor inhibitors","volume":"84","author":"Patel","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0265","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1128\/CVI.00175-10","article-title":"Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study","volume":"17","author":"Chioato","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0270","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/JAA.S172338","article-title":"Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the phase IIIb ALIZE trial","author":"Zeitlin","year":"2018","journal-title":"Journal of Asthma and Allergy"},{"key":"10.1016\/j.vaccine.2026.128399_bb0275","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001018","article-title":"Secukinumab does not impair the immunogenic response to the influenza vaccine in patients","volume":"5","author":"Richi","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.vaccine.2026.128399_bb0280","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/14397595.2013.843743","article-title":"Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab","volume":"24","author":"Tsuru","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0285","article-title":"High immunogenicity to influenza vaccination in Crohn\u2019s disease patients treated with ustekinumab","volume":"8","author":"Doornekamp","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128399_bb0290","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0295","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-012-9813-x","article-title":"Rituximab-treated patients have a poor response to influenza vaccination","volume":"33","author":"Eisenberg","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0300","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.vaccine.2010.12.072","article-title":"The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab","volume":"29","author":"Arad","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128399_bb0305","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vaccine.2026.128399_bb0310","article-title":"Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination?: a systematic review and Meta-analysis","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vaccine.2026.128399_bb0315","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.102996","article-title":"Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patients","volume":"135","author":"Ten Hagen","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2026.128399_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102927","article-title":"Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis","volume":"21","author":"Jena","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.vaccine.2026.128399_bb0330","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1016\/S2665-9913(22)00034-0","article-title":"Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study","volume":"4","author":"Wieske","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0335","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/art.42153","article-title":"Immunogenicity and safety of standard and third-dose SARS-CoV-2 vaccination in patients receiving immunosuppressive therapy","volume":"74","author":"Syversen","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0340","article-title":"Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab","volume":"13","author":"Lin","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128399_bb0345","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard-2022-222550","article-title":"Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study","volume":"81","author":"Furer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0350","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S2468-1253(22)00274-6","article-title":"COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study","volume":"7","author":"Alexander","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0355","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002871","article-title":"Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2)","volume":"9","author":"Tran","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.vaccine.2026.128399_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106282","article-title":"Comparison of short- and long-term humoral immune responses to pneumococcal polysaccharide and glycoconjugate vaccines in an HIV-infected population","volume":"89","author":"Faustini","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2026.128399_bb0365","article-title":"Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients","volume":"22","author":"Nived","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.vaccine.2026.128399_bb0370","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1016\/j.vaccine.2018.07.039","article-title":"The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis","volume":"36","author":"van Aalst","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128399_bb0375","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.vaccine.2026.128399_bb0380","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/art.30580","article-title":"Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors","volume":"63","author":"Kapetanovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vaccine.2026.128399_bb0385","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s10067-011-1856-5","article-title":"Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs","volume":"30","author":"Kapetanovic","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0390","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0395","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1883-1","article-title":"Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy","volume":"21","author":"Winthrop","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.vaccine.2026.128399_bb0400","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/ajg.2012.79","article-title":"Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease","volume":"107","author":"Gisbert","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0405","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/21645515.2019.1574151","article-title":"High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study","volume":"15","author":"Haykir Solay","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128399_bb0410","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-020-0410-x","article-title":"Maintenance of antibody response to diphtheria\/tetanus vaccine in patients aged 2-5years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept","volume":"18","author":"Brunner","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.vaccine.2026.128399_bb0415","doi-asserted-by":"crossref","DOI":"10.1186\/1546-0096-13-S1-P1","article-title":"Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab","volume":"13","author":"Brogan","year":"2015","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0420","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/MIB.0b013e318281341b","article-title":"Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease","volume":"19","author":"Jacobson","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0425","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1136\/annrheumdis-2013-203429","article-title":"Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study","volume":"73","author":"Heijstek","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0430","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jama.2024.25395","article-title":"Antibody response to respiratory syncytial virus vaccination in immunocompromised persons","volume":"333","author":"Karaba","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128399_bb0435","article-title":"Immunogenicity and safety of the bivalent respiratory syncytial virus prefusion F subunit vaccine in immunocompromised or renally impaired adults","volume":"13","author":"Almeida","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128399_bb0440","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1182\/blood-2011-08-372649","article-title":"Rituximab blocks protective serologic response to influenza a (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment","volume":"118","author":"Yri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2026.128399_bb0445","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling","volume":"122","author":"de Lavallade","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2026.128399_bb0450","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1001\/jamaoncol.2016.2437","article-title":"Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with Ibrutinib","volume":"2","author":"Sun","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0455","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.3324\/haematol.2017.164285","article-title":"Ibrutinib may impair serological responses to influenza vaccination","volume":"102","author":"Abby","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.vaccine.2026.128399_bb0460","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1002\/jmv.27956","article-title":"Impaired serological response to COVID-19 vaccination following anticancer therapy: a systematic review and meta-analysis","volume":"94","author":"Tang","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0465","first-page":"185","article-title":"Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines","volume":"137","author":"Pleyer","year":"2021","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.vaccine.2026.128399_bb0470","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/bloodadvances.2021006574","article-title":"BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL","volume":"6","author":"Pleyer","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.vaccine.2026.128399_bb0475","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2008.120","article-title":"Immune response to influenza vaccine in children with inflammatory bowel disease","volume":"104","author":"Lu","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0480","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.vaccine.2014.12.030","article-title":"Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy","volume":"33","author":"Aikawa","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128399_bb0485","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3109\/s10165-012-0595-z","article-title":"Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab","volume":"22","author":"Shinoki","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0490","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/03009742.2012.709272","article-title":"Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis","volume":"42","author":"Aikawa","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0495","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-017-0190-0","article-title":"Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay","volume":"15","author":"Camacho-Lovillo","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.vaccine.2026.128399_bb0500","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.vaccine.2011.11.083","article-title":"Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis","volume":"30","author":"Dell\u2019Era","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128399_bb0505","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/rheumatology\/kez045","article-title":"Safety and immunogenicity of tetanus\/diphtheria vaccination in patients with rheumatic diseases\u2014a prospective multi-Centre cohort study","volume":"58","author":"B\u00fchler","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.vaccine.2026.128399_bb0510","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s10620-018-5043-2","article-title":"Lower sustained diphtheria and pertussis antibody concentrations in inflammatory bowel disease patients","volume":"63","author":"Caldera","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.vaccine.2026.128399_bb0515","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vaccine.2026.128399_bb0520","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.vaccine.2026.128399_bb0525","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128399_bb0530","series-title":"Immunisation Handbook: Section 4: Immunisation of special groups - 4.3 Immunocompromised individuals","author":"Ministry of Health","year":"2020"},{"key":"10.1016\/j.vaccine.2026.128399_bb0535","series-title":"Canadian immunization guide - part 3 - vaccination of specific populations: Immunization of immunocompromised persons","author":"PHAC","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128399_bb0540","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/rheumatology\/ken436","article-title":"Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept","volume":"48","author":"Borte","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vaccine.2026.128399_bb0545","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/acr.20045","article-title":"Yellow fever revaccination during infliximab therapy","volume":"62","author":"Scheinberg","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.vaccine.2026.128399_bb0550","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.vaccine.2016.01.037","article-title":"Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication","volume":"34","author":"Wieten","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128399_bb0555","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jacig.2021.12.003","article-title":"Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines","volume":"1","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.vaccine.2026.128399_bb0560","doi-asserted-by":"crossref","first-page":"8024","DOI":"10.1016\/j.vaccine.2020.10.028","article-title":"Varicella-zoster-virus vaccination of immunosuppressed children with inflammatory bowel disease or autoimmune hepatitis: a prospective observational study","volume":"38","author":"Seitel","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128399_bb0565","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-018-0235-z","article-title":"The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey","volume":"16","author":"Jeyaratnam","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.vaccine.2026.128399_bb0570","article-title":"Predictive markers of immunogenicity and efficacy for human vaccines","volume":"9","author":"Van Tilbeurgh","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128399_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.559590","article-title":"Artificial intelligence applied to in vitro gene expression testing (IVIGET) to predict trivalent inactivated influenza vaccine immunogenicity in HIV infected children","volume":"11","author":"Cotugno","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128399_bb0580","first-page":"177","article-title":"Mathematical modeling provides kinetic details of the human immune response to vaccination","volume":"4","author":"Le","year":"2014","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:26:04Z","timestamp":1783376764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":116,"alternative-id":["S0264410X26002070"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128399","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunisation against vaccine-preventable diseases in individuals receiving immunosuppressive targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128399"}}